[go: up one dir, main page]

PT1178810E - Utilizacao de acidos bisfosfonicos para o tratamento de angiogenese - Google Patents

Utilizacao de acidos bisfosfonicos para o tratamento de angiogenese

Info

Publication number
PT1178810E
PT1178810E PT00936760T PT00936760T PT1178810E PT 1178810 E PT1178810 E PT 1178810E PT 00936760 T PT00936760 T PT 00936760T PT 00936760 T PT00936760 T PT 00936760T PT 1178810 E PT1178810 E PT 1178810E
Authority
PT
Portugal
Prior art keywords
treatment
patient
angiogenese
bisphosphonic acids
bisphosphonate
Prior art date
Application number
PT00936760T
Other languages
English (en)
Inventor
Jonathan Green
Jeanette Marjorie Wood
Okuno Tetsuji
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1178810(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9911926.5A external-priority patent/GB9911926D0/en
Priority claimed from GBGB9925131.6A external-priority patent/GB9925131D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1178810E publication Critical patent/PT1178810E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT00936760T 1999-05-21 2000-05-19 Utilizacao de acidos bisfosfonicos para o tratamento de angiogenese PT1178810E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9911926.5A GB9911926D0 (en) 1999-05-21 1999-05-21 Organic compounds
GBGB9925131.6A GB9925131D0 (en) 1999-10-22 1999-10-22 Organic compounds

Publications (1)

Publication Number Publication Date
PT1178810E true PT1178810E (pt) 2005-08-31

Family

ID=26315578

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00936760T PT1178810E (pt) 1999-05-21 2000-05-19 Utilizacao de acidos bisfosfonicos para o tratamento de angiogenese

Country Status (21)

Country Link
US (2) US20020142996A1 (pt)
EP (1) EP1178810B8 (pt)
JP (1) JP2003500352A (pt)
KR (1) KR100763064B1 (pt)
CN (1) CN1202828C (pt)
AT (1) ATE293450T1 (pt)
AU (1) AU775079B2 (pt)
BR (1) BR0010808A (pt)
CA (1) CA2374049A1 (pt)
DE (1) DE60019580T2 (pt)
DK (1) DK1178810T3 (pt)
ES (1) ES2240106T3 (pt)
HU (1) HUP0201329A3 (pt)
IL (2) IL146520A0 (pt)
NO (1) NO322212B1 (pt)
NZ (1) NZ515541A (pt)
PL (1) PL351674A1 (pt)
PT (1) PT1178810E (pt)
SK (1) SK16682001A3 (pt)
TW (1) TWI224504B (pt)
WO (1) WO2000071104A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1296689B3 (en) * 2000-06-20 2013-02-13 Novartis AG Method of administering bisphosphonates
SI1296689T1 (sl) * 2000-06-20 2006-08-31 Novartis Ag Nacin dajanja pacientu bisfosfonatov
WO2002062351A1 (en) * 2001-02-06 2002-08-15 The Royal Alexandra Hospital For Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
KR20040015230A (ko) * 2001-05-02 2004-02-18 노파르티스 아게 비스포스포네이트의 제약학적 용도
EP1406910B1 (fr) * 2001-07-16 2010-01-13 Universite Paris 13 Procedes de preparation de derives de bisphosphonates
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20050084489A1 (en) * 2002-03-04 2005-04-21 Wilder Ronald L. Methods of preventing or treating disorders by administering and integrin alphanubeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
CA2763775C (en) 2002-05-10 2014-01-07 F. Hoffmann-La Roche Ag Bisphosphonic acids for the treatment and prevention of osteoporosis
EP1426052B1 (en) * 2002-12-02 2009-09-02 Innate Pharma Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof
AU2004262903B2 (en) * 2003-07-21 2007-08-23 Novartis Ag Combinations of a Cathepsin K inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
SK50782006A3 (sk) † 2004-02-26 2007-03-01 Zentiva, A. S. Amorfné formy risedronátu monosodného
PT1713489E (pt) * 2004-08-23 2011-03-03 Teva Pharma Forma cristalina de ibandronato de sódio e processos para a sua preparação
US7914810B2 (en) * 2005-05-06 2011-03-29 Synthes Usa, Llc Methods for the in situ treatment of bone cancer
PE20070360A1 (es) * 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
EP2255199A1 (en) * 2008-02-19 2010-12-01 Jovesis Inc. Microparticle compositions to modify cancer promoting cells
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
SI2459176T1 (en) 2009-07-31 2018-01-31 Gruenenthal Gmbh Crystallization process and bioavailability
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
WO2015018659A1 (en) * 2013-08-05 2015-02-12 Vib Vzw Glutamine synthetase inhibitors for inhibition of pathological angiogenesis
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
DE3425812A1 (de) * 1984-07-13 1986-01-16 Deutsches Krebsforschungszentrum, 6900 Heidelberg Neue 1-hydroxy-1,1-diphosphonsaeureverbindungen, verfahren zu ihrer herstellung und pharmakologische zubereitungen, insbesondere zur behandlung von knochentumoren
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
SE9402001D0 (sv) * 1994-06-09 1994-06-09 Leiras Oy Pyridylbisphosphonates for use as a therapeutical agent
IT1290444B1 (it) * 1997-03-27 1998-12-03 Boehringer Mannheim Italia Coniugati di bis-fosfonati con funzionalita' alchilanti aventi attivita' antitumorale
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
EP1132088A3 (en) * 1997-07-22 2002-04-24 MERCK & CO. INC. Method for inhibiting bone resorption
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6555529B1 (en) * 1997-12-25 2003-04-29 Toray Industries, Inc. Remedies for intramedullary diseases
US6416964B2 (en) * 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
WO1999038998A1 (en) * 1998-01-29 1999-08-05 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US6416737B1 (en) * 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance

Also Published As

Publication number Publication date
AU5214100A (en) 2000-12-12
SK16682001A3 (sk) 2002-04-04
KR100763064B1 (ko) 2007-10-04
DE60019580T2 (de) 2006-03-09
PL351674A1 (en) 2003-05-19
NO322212B1 (no) 2006-08-28
ATE293450T1 (de) 2005-05-15
EP1178810B8 (en) 2005-07-27
CN1202828C (zh) 2005-05-25
JP2003500352A (ja) 2003-01-07
EP1178810A2 (en) 2002-02-13
NO20015638D0 (no) 2001-11-19
NZ515541A (en) 2003-03-28
CA2374049A1 (en) 2000-11-30
HUP0201329A2 (en) 2002-08-28
US20020142996A1 (en) 2002-10-03
DK1178810T3 (da) 2005-07-11
CN1384749A (zh) 2002-12-11
BR0010808A (pt) 2002-08-27
IL146520A0 (en) 2002-07-25
EP1178810B1 (en) 2005-04-20
KR20010113830A (ko) 2001-12-28
WO2000071104A3 (en) 2001-07-19
US20040176327A1 (en) 2004-09-09
IL146520A (en) 2006-09-05
WO2000071104A2 (en) 2000-11-30
DE60019580D1 (de) 2005-05-25
AU775079B2 (en) 2004-07-15
TWI224504B (en) 2004-12-01
NO20015638L (no) 2002-01-15
HUP0201329A3 (en) 2005-02-28
ES2240106T3 (es) 2005-10-16

Similar Documents

Publication Publication Date Title
PT1178810E (pt) Utilizacao de acidos bisfosfonicos para o tratamento de angiogenese
IL155363A0 (en) Use of bisphosphonates for pain treatment
Vepsalainen Bisphosphonate prodrugs
CY1106482T1 (el) Φαρμακευτικη παρεντepικη συνθεση πepιεχοντας ενα διφωσφονικο
DK0756484T3 (da) Vådgranuleringsformulering til diphosphonsyrer
DE602004024545D1 (de) Indungen
Saad Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone
CA2409930A1 (en) Use of zoledronate for the manufacture of a medicament for the treatment of bone metabolism diseases
EA200100080A1 (ru) Лекарственные средства, содержащие бисфосфоновые кислоты и их производные, предназначенные для профилактики и лечения аутоиммунных заболеваний и аллергий
PT1803727E (pt) Processo melhorado para o fabrico de ácido 4-amino-hidroxibutilideno-1,1 bisfosfónico e seus sais
TH51552A (th) การใช้กรดบิสฟอสโฟนิคสำหรับการบำบัดแอนจิโอจีนีซิส
DE60235085D1 (de) Herstellungsverfahren von derivate von bisphosphonaten